OneSpaWorld Holdings announced a partnership with Niagen Bioscience to offer Niagen IV, a 500 mg pharmaceutical‑grade NAD‑boosting intravenous therapy, at more than 80 medi‑spa clinics on its cruise‑ship fleet. The collaboration, disclosed on March 31 2026, will make the company the first to provide NAD‑IV therapy at sea.
The partnership is a strategic fit for OneSpaWorld’s high‑margin medi‑spa business, which already generates a significant portion of the company’s revenue from onboard wellness services. By adding Niagen IV, the company aims to attract a new segment of health‑conscious passengers and increase average spend per guest in its premium medi‑spa category. CEO Leonard Fluxman said, “Today’s travelers are increasingly seeking science‑backed wellness experiences while at sea. Niagen IV offers a premium NAD‑boosting intravenous solution, providing a premium and innovative service enhancement for travelers committed to prioritizing health and longevity.”
OneSpaWorld’s FY 2025 results—record revenue of $961 million and adjusted EBITDA of $123.3 million—demonstrate the company’s strong financial foundation, although net income was impacted by restructuring charges related to exiting land‑based operations. Niagen Bioscience, a publicly traded company on NASDAQ (ticker NAGE), brings a proven NAD+ science platform and a next‑generation IV formulation that offers faster infusion times and potentially fewer side effects. The partnership expands Niagen’s clinical channel into a high‑intensity, high‑visibility environment and provides OneSpaWorld with a differentiated, science‑backed wellness offering that can drive higher margins and customer loyalty.
The collaboration positions OneSpaWorld as a pioneer in the emerging NAD‑IV therapy market at sea, giving it a competitive advantage over other cruise operators that rely on conventional spa services. For Niagen Bioscience, the deal opens a new consumer segment—high‑intent, on‑vacation travelers—complementing its existing network of healthcare, wellness, and longevity clinics. While specific rollout timelines, pricing, and the cruise lines involved have not been disclosed, the partnership is expected to enhance OneSpaWorld’s high‑value medi‑spa segment and contribute to future revenue growth.
The announcement is a material event that could influence OneSpaWorld’s revenue trajectory and competitive positioning. It underscores the company’s commitment to innovation in wellness services and aligns with broader industry trends toward science‑backed, premium health experiences for travelers.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.